0.3684
price up icon6.32%   0.028
after-market アフターアワーズ: .37 0.0016 +0.43%
loading
前日終値:
$0.3404
開ける:
$0.34
24時間の取引高:
1.53M
Relative Volume:
0.68
時価総額:
$58.05M
収益:
-
当期純損益:
$-101.17M
株価収益率:
-0.3542
EPS:
-1.04
ネットキャッシュフロー:
$-96.57M
1週間 パフォーマンス:
-11.73%
1か月 パフォーマンス:
-27.04%
6か月 パフォーマンス:
-59.64%
1年 パフォーマンス:
-54.82%
1日の値動き範囲:
Value
$0.3336
$0.3725
1週間の範囲:
Value
$0.3149
$0.41
52週間の値動き範囲:
Value
$0.2612
$1.60

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name
名前
X 4 Pharmaceuticals Inc
Name
セクター
Healthcare (1196)
Name
電話
857-529-8300
Name
住所
61 NORTH BEACON STREET, BOSTON, MA
Name
職員
143
Name
Twitter
@x4pharma
Name
次回の収益日
2024-11-13
Name
最新のSEC提出書
Name
XFOR's Discussions on Twitter

XFOR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
XFOR 0.3702 58.05M 0 -101.17M -96.57M -1.04
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 24.89B 3.30B -501.07M 1.03B 11.54

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-08-30 再開されました B. Riley Securities Buy
2022-12-22 開始されました Cantor Fitzgerald Overweight
2022-12-12 開始されました Piper Sandler Overweight
2019-12-23 開始されました Oppenheimer Outperform
2019-12-18 開始されました ROTH Capital Buy
2019-12-09 アップグレード Citigroup Neutral → Buy
2019-12-05 開始されました B. Riley FBR Buy
2019-06-07 開始されました Stifel Buy
2019-06-05 開始されました Cowen Outperform
すべてを表示

X 4 Pharmaceuticals Inc (XFOR) 最新ニュース

pulisher
02:13 AM

Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace

02:13 AM
pulisher
04:15 AM

Atenolol Global Market 2024 – Top Manufacturers, Latest Trends, Future Prospects And Outlook By 2033 - WhaTech

04:15 AM
pulisher
01:17 AM

B. Riley Predicts Increased Earnings for X4 Pharmaceuticals - Defense World

01:17 AM
pulisher
Nov 20, 2024

Spotlight On 3 US Penny Stocks With At Least $60M Market Cap - Simply Wall St

Nov 20, 2024
pulisher
Nov 20, 2024

B. Riley Expects Stronger Earnings for X4 Pharmaceuticals - MarketBeat

Nov 20, 2024
pulisher
Nov 20, 2024

Top 10 pharma companies in India by market cap [2024] - Forbes India

Nov 20, 2024
pulisher
Nov 20, 2024

Benzodiazepine Drugs Market Overview: Industry Insights, Demand Trends, Competitive Landscape, and Key Inno... - WhaTech

Nov 20, 2024
pulisher
Nov 19, 2024

Chronic Pain Market Set for Steady Growth with 4% CAGR Driven by Drugs and Devices | Future Market Insights, Inc. - GlobeNewswire

Nov 19, 2024
pulisher
Nov 18, 2024

10 Biggest Biotechnology Companies - Investopedia

Nov 18, 2024
pulisher
Nov 18, 2024

HC Wainwright Predicts Lower Earnings for X4 Pharmaceuticals - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024
pulisher
Nov 15, 2024

RFK Jr vow to purge FDA sets up collision with Big Pharma - Reuters.com

Nov 15, 2024
pulisher
Nov 15, 2024

Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary - Fast Company

Nov 15, 2024
pulisher
Nov 14, 2024

Earnings call: X4 Pharmaceuticals reports progress in CN treatment By Investing.com - Investing.com Nigeria

Nov 14, 2024
pulisher
Nov 14, 2024

CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28% - Simply Wall St

Nov 14, 2024
pulisher
Nov 14, 2024

XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia… - Zacks Small Cap Research

Nov 14, 2024
pulisher
Nov 14, 2024

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline - Quantisnow

Nov 14, 2024
pulisher
Nov 14, 2024

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ... - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

X4 Pharmaceuticals: Q3 Earnings Snapshot - Houston Chronicle

Nov 14, 2024
pulisher
Nov 13, 2024

Stifel cuts X4 Pharmaceuticals target to $4, maintains Buy - Investing.com

Nov 13, 2024
pulisher
Nov 13, 2024

X4 Pharmaceuticals: Promising Phase 2 Trial Results - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

X4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) - Marketscreener.com

Nov 13, 2024
pulisher
Nov 13, 2024

Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com - Defense World

Nov 13, 2024
pulisher
Nov 12, 2024

Xenon Reports Q3 2024 Financial Results and Business Update - The Manila Times

Nov 12, 2024
pulisher
Nov 12, 2024

SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Quantisnow

Nov 12, 2024
pulisher
Nov 10, 2024

Great week for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) institutional investors after losing 18% over the previous year - Simply Wall St

Nov 10, 2024
pulisher
Nov 08, 2024

X4 Pharmaceuticals Inc (XFOR) Has A Gold Mine On Its Hands - Stocks Register

Nov 08, 2024
pulisher
Nov 07, 2024

Global Respiratory Disease Testing Market to Grow at a CAGR of ~4% by 2030 | DelveInsight - The Malaysian Reserve

Nov 07, 2024
pulisher
Nov 07, 2024

C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Ionis to present at upcoming investor conferences - Quantisnow

Nov 07, 2024
pulisher
Nov 06, 2024

Glenmark Pharmaceuticals Ltd. Sees -4.19% Decline in Stock Price, Rated 'Hold' by MarketsMOJO - MarketsMojo

Nov 06, 2024
pulisher
Nov 06, 2024

DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update - Quantisnow

Nov 06, 2024
pulisher
Nov 06, 2024

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - The Malaysian Reserve

Nov 06, 2024
pulisher
Nov 06, 2024

Global Molecular Modeling Market to Hit USD 19.47 Billion by 2032, Driven by Demand for Drug Discovery Innovation and Advanced Computational Tools | Research by SNS Insider - 新浪香港

Nov 06, 2024
pulisher
Nov 06, 2024

X4 Pharmaceuticals (XFOR) to Release Earnings on Wednesday - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition - Quantisnow

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in X4 Pharmaceuticals Inc - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Top 50 Pharma: Oncology patent leaders 2024 - Drug Discovery & Development

Nov 04, 2024
pulisher
Nov 04, 2024

Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - Quantisnow

Nov 04, 2024
pulisher
Nov 04, 2024

H.C. Wainwright reiterated coverage on Viking Therapeutics with a new price target - Quantisnow

Nov 04, 2024
pulisher
Nov 04, 2024

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - The Manila Times

Nov 04, 2024
pulisher
Nov 04, 2024

Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 - PR Newswire

Nov 04, 2024
pulisher
Nov 03, 2024

Sun Pharma shares tumble 4% as US court blocks Leqselvi launch - The Economic Times

Nov 03, 2024
pulisher
Nov 01, 2024

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024
pulisher
Nov 01, 2024

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - The Manila Times

Nov 01, 2024
pulisher
Nov 01, 2024

9 Best Biotech Stocks Of November 2024 - Forbes

Nov 01, 2024
pulisher
Nov 01, 2024

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024

X 4 Pharmaceuticals Inc (XFOR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$194.56
price up icon 0.07%
$108.23
price up icon 5.98%
大文字化:     |  ボリューム (24 時間):